X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VB-421 (lonigutamab) is a subcutaneously delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). It is being evaluated for the treatment of thyroid eye disease.
Lead Product(s): Lonigutamab
Therapeutic Area: Immunology Product Name: VB-421
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
ABY-035 (izokibep) is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity. It is being evaluated for the treatment of psoriatic arthritis.
Lead Product(s): Izokibep
Therapeutic Area: Immunology Product Name: ABY 035
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
ABY-035 (izokibep) is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity. It is being evaluated for the treatment of hidradenitis suppurativa.
Lead Product(s): Izokibep
Therapeutic Area: Dermatology Product Name: ABY 035
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity. It is being evaluated in phase 2/3 clinical trials for the treatment of psoriatic arthritis (PsA).
Lead Product(s): Izokibep
Therapeutic Area: Immunology Product Name: ABY-035
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A). It is designed to overcome monoclonal antibodies limitations for hidradenitis suppurativa indication. It is being investigated for moderate-to-severe Hidradenitis.
Lead Product(s): Izokibep
Therapeutic Area: Dermatology Product Name: IMG-020
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Company will use the proceeds to fund its operations, including the development of pipeline including Izokibep and commercialization activities, business development activities, and capital expenditures.
Lead Product(s): Izokibep
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $621.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 09, 2023
Details:
The net proceeds will be used to advance the clinical development of izokibep through topline data in Phase 2b/3 trials of izokibep in each of HS, PsA, and uveitis.
Lead Product(s): Izokibep
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $540.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 04, 2023
Details:
IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A). It is designed to overcome monoclonal antibodies limitations for hidradenitis suppurativa indication. It is being investigated for psoriatic arthritis.
Lead Product(s): Izokibep
Therapeutic Area: Immunology Product Name: IMG-020
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A), adinistered via subcutaneous injection. It is designed to overcome monoclonal antibodies limitations for Hidradenitis Suppurativa indication.
Lead Product(s): Izokibep
Therapeutic Area: Dermatology Product Name: IMG-020
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Izokibep (IMG-020), is a unique interleukin- 17A inhibitor designed to overcome the limitations of monoclonal antibodies by utilizing high potency and small molecular size to enable high drug exposure levels through a single, subcutaneous injection.
Lead Product(s): Izokibep
Therapeutic Area: Immunology Product Name: IMG-020
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
